EligibleTrials

Treatment and Clinical Outcomes Among SLE Patients in Pregnancy

Recruiting · NCT04976465 · Interventional (participants receive a specific treatment) · Lead sponsor: Qilu Hospital of Shandong University

View the official record on ClinicalTrials.gov →
Lupus

Interventions studied

AnticoagulationWithout Anticoagulation

What this trial is about

Systemic lupus erythematosus (SLE) is a kind of systemic autoimmune disease which can cause multiple organs and system damage, which often occurs in women of childbearing age. Compared with healthy pregnant women, SLE patients have higher incidence of premature delivery, preeclampsia and fetal loss during pregnancy. Since SLE patients usually have disease activity during pregnancy and postpartum, and a variety of maternal and fetal diseases are closely related to SLE, it is very important to monitor the disease activity and drug treatment of SLE patients during pregnancy.

Who can take part

Age range
20 Years to 45 Years
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)

Inclusion criteria

Exclusion criteria

Where it is running

1 location listed.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.